



Actor portrayal

NOW APPROVED

Ekterly[®]
(sebetralstat) tablets 300 mg

Talking with your patients about EKTERLY

Review your patient's HAE experience, and evaluate potential updates to their treatment plan

Educate your patients on the importance of on-demand treatment in HAE management, and encourage them to follow these US HAEA Guidelines¹:



Keep on-demand
treatment
immediately available



Treat early to stop
attacks from
getting worse



All attacks are eligible for
treatment regardless of
location or severity

HAE=hereditary angioedema; US HAEA=US Hereditary Angioedema Association.

INDICATION

EKTERLY[®] (sebetralstat) is a plasma kallikrein inhibitor indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.

IMPORTANT SAFETY INFORMATION

Adverse reactions: The most commonly reported adverse reaction was headache.

Please see additional Important Safety Information throughout.
Please see full [Prescribing Information](#).

Use the questions below to learn more about your patient's experience living with HAE

Multiple answers may be appropriate for some questions.

1. How many of your HAE attacks do you treat?

- | | |
|---------------------------------------|---------------------------------------|
| <input type="checkbox"/> All of them | <input type="checkbox"/> Some of them |
| <input type="checkbox"/> Most of them | <input type="checkbox"/> None of them |

2. Which areas are typically affected during an attack?

- | | | |
|--|--|-------------------------------|
| <input type="checkbox"/> Extremities (hands, feet, legs) | <input type="checkbox"/> Larynx (throat) | <input type="checkbox"/> Face |
| <input type="checkbox"/> Abdomen (stomach) | <input type="checkbox"/> Genitals | |

3. What triggers your attacks?

- | | | |
|---|---|--------------------------------------|
| <input type="checkbox"/> Mental or physical stress | <input type="checkbox"/> Certain foods | <input type="checkbox"/> Medications |
| <input type="checkbox"/> Excitement, fear, or worry | <input type="checkbox"/> Hormonal changes | <input type="checkbox"/> Other _____ |
| <input type="checkbox"/> Illness or infection | <input type="checkbox"/> Trauma (includes medical procedures) | |

4. How would you rate the severity of your attacks?

- | | |
|-----------------------------------|--------------------------------------|
| <input type="checkbox"/> Mild | <input type="checkbox"/> Severe |
| <input type="checkbox"/> Moderate | <input type="checkbox"/> Very severe |

5. How many times during the past year have you visited the emergency room for an attack?

- | | | |
|------------------------------|------------------------------|------------------------------|
| <input type="checkbox"/> 0 | <input type="checkbox"/> 3-5 | <input type="checkbox"/> 8-9 |
| <input type="checkbox"/> 1-2 | <input type="checkbox"/> 6-7 | <input type="checkbox"/> 10+ |

6. How often do your attacks disrupt important activities, like work or school?

- | | | |
|--|---|---------------------------------------|
| <input type="checkbox"/> Once a week | <input type="checkbox"/> A few times per week | <input type="checkbox"/> Once a month |
| <input type="checkbox"/> A few times per month | <input type="checkbox"/> A few times per year | <input type="checkbox"/> Never |

Please see additional Important Safety Information throughout.
Please see full [Prescribing Information](#).

Ekterly[®]
(sebetralstat) tablets 300 mg

7. What challenges do you face with your current on-demand treatment?


- | | | |
|---|--|---|
| <input type="checkbox"/> Medication is expensive | <input type="checkbox"/> Lack of a private place to inject/prefer to treat at home | <input type="checkbox"/> Prefer to “save” doses for more severe attacks |
| <input type="checkbox"/> Medication is bulky to carry | <input type="checkbox"/> Lack of time to prepare treatment | <input type="checkbox"/> Treatment is painful |
| <input type="checkbox"/> Fear of needles | <input type="checkbox"/> Other _____ | |

8. What factors are most important when considering a change to your treatment plan?

- | | | |
|---|--|--|
| <input type="checkbox"/> How well it fits into your lifestyle | <input type="checkbox"/> Potential reactions to medication | <input type="checkbox"/> How convenient and portable it is |
| <input type="checkbox"/> Administration (injection, infusion, oral) | <input type="checkbox"/> How easy it is to use | <input type="checkbox"/> How quickly it resolves attacks |

EKTERLY is the first and only oral on-demand treatment that lets patients treat at attack recognition^{2,3}

Median Time to Treatment From Attack Onset^{4,5}



One 600-mg dose can provide symptom relief²

- One 600-mg dose is two 300-mg tablets
- EKTERLY 300 mg is not a recommended dose for treatment
- May be taken with or without food
- No preparation, setup, or refrigeration required
- Safety profile similar to placebo

*KONFIDENT was a multinational, randomized, double-blind, placebo-controlled, phase 3, crossover study of 136 patients from 17 countries. Study participants were randomized to receive either placebo, EKTERLY 300 mg, or EKTERLY 600 mg to treat 3 attacks in a 3-way crossover design using 1 of 6 treatment sequences.^{4,6}

†KONFIDENT-S is a multicenter, open-label extension trial of 134 adult and adolescent (≥12 years of age) patients. Study participants had a confirmed diagnosis of HAE and ≥2 attacks within 3 months and were enrolled after completing the KONFIDENT phase 3 trial or de novo.^{5,7}

IMPORTANT SAFETY INFORMATION

Drug interactions: EKTERLY is a substrate of CYP3A4. Concomitant use of EKTERLY with a strong CYP3A4 inhibitor increases sebetralstat exposure, which may increase the risk of sebetralstat adverse reactions. Avoid use of EKTERLY with strong CYP3A4 inhibitors and reduce the dose of EKTERLY to one dose of 300 mg (one tablet) with moderate CYP3A4 inhibitors. Concomitant use of EKTERLY with a strong or moderate CYP3A4 inducer decreases sebetralstat exposure, which may decrease efficacy. The use of EKTERLY with strong or moderate CYP3A4 inducers is not recommended.

Please see additional Important Safety Information throughout.
Please see full [Prescribing Information](#).

Ekterly[®]
(sebetralstat) tablets 300 mg

With the flexibility to **treat HAE attacks whenever they occur and wherever your patients are**, consider prescribing oral on-demand EKTERLY²



INDICATION

EKTERLY[®] (sebetralstat) is a plasma kallikrein inhibitor indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.

IMPORTANT SAFETY INFORMATION

Adverse reactions: The most commonly reported adverse reaction was headache.

Drug interactions: EKTERLY is a substrate of CYP3A4. Concomitant use of EKTERLY with a strong CYP3A4 inhibitor increases sebetralstat exposure, which may increase the risk of sebetralstat adverse reactions. Avoid use of EKTERLY with strong CYP3A4 inhibitors and reduce the dose of EKTERLY to one dose of 300 mg (one tablet) with moderate CYP3A4 inhibitors. Concomitant use of EKTERLY with a strong or moderate CYP3A4 inducer decreases sebetralstat exposure, which may decrease efficacy. The use of EKTERLY with strong or moderate CYP3A4 inducers is not recommended.

Use in specific populations: Avoid use of EKTERLY in patients with severe hepatic impairment (Child-Pugh Class C). The recommended dosage of EKTERLY is one dose of 300 mg (one tablet) in patients with moderate hepatic impairment (Child-Pugh Class B).

There are no available data on EKTERLY in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. There are no data on the presence of sebetralstat or its metabolite in human milk, the effects on the breastfed infant, or the effects on milk production.

The safety and effectiveness of EKTERLY in pediatric patients aged under 12 years of age have not been established.

To report SUSPECTED ADVERSE REACTIONS, contact KalVista Pharmaceuticals, Inc. at **1-855-258-4782** or FDA at **1-800-FDA-1088** or www.fda.gov/medwatch.

Please see the full [Prescribing Information](#).

References: **1.** Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. *J Allergy Clin Immunol Pract.* 2021;9(1):132-150.e3. doi:10.1016/j.jaip.2020.08.046 **2.** EKTERLY. Package insert. KalVista Pharmaceuticals, Inc.; 2025. **3.** KalVista Pharmaceuticals announces FDA approval of EKTERLY (sebetralstat), first and only oral on demand treatment for hereditary angioedema. Published July 2025. Accessed July 2025. **4.** Riedl MA, Farkas H, Aygören-Pürsün E, et al. Oral sebetralstat for on-demand treatment of hereditary angioedema attacks. *N Engl J Med.* 2024;391(1):32-43. doi:10.1056/NEJMoa2314192 **5.** Data on File. KalVista Pharmaceuticals, Inc. 2024. **6.** Riedl MA, Farkas H, Aygören-Pürsün E, et al. Oral sebetralstat for on-demand treatment of hereditary angioedema attacks. *N Engl J Med.* 2024;391(1) (suppl 1):1-33. doi:10.1056/NEJMoa2314192 **7.** Data on File. KalVista Pharmaceuticals, Inc. 2024.